TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation

A multicentre observational study on treatment approaches and HER2 positive status prevalence in different stages of bladder cancer and PD-L1-positive status in metastatic bladder cancer in Russian Federation

Inclusion Criteria: * Age ≥ 18 years; * Signed ICF, including consent for FFPE tumor tissue sample testing; * Confirmed diagnosis of urothelial bladder cancer at NMIBC, MIBC, or mBC stage at study entry; * For patients with NMIBC: 1. TURBT performed at least 1 month but not more than 12 months prior to study entry; 2. Presence of ≥1 high-risk feature: * T1 tumor * High grade/G3 tumor * CIS (carcinoma in situ) * Multiple and recurrent and large (with diameter of largest tumor ≥3 cm) tumors (all conditions must be met in this point); * For patients with MIBC: Сystectomy performed at least 2 months but not more than 12 months prior to study entry; * For patients with mBC: mBC diagnosed during 12 months prior to study entry; * Availability of medical history data; * Availability of FFPE tumour tissue sample obtained during biopsy and/or surgery. Exclusion Criteria: • Participation in any interventional trial since the urothelial bladder cancer diagnosis.